Download our sample post-conference report now or receive the full version by contacting us.
The 2022 ASCO Annual Meeting has concluded and in its wake lies 93 bispecific-related abstracts that have been carefully screened and added to the Beacon database. Of these 93 abstracts, 90 presented clinical trial data, and the remaining 3 presented preclinical data.
T cell engagers were the most investigated bispecific assets. The majority of the abstracts presented by disease indication were for solid tumors accounting for 60% of the abstracts, followed by 34% for blood cancer. There are currently 6 trials presenting phase 3 trial data for solid tumors and blood cancer.
For more insight please download the sample, contact us, or request a demo.
Find out more
This insight and data is part of the subscription to Beacon Bispecific.
Speak with our Team
Our dedicated team is on hand to showcase how Beacon can help you find the answers to your bispecific questions.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements